Product logins

Find logins to all Clarivate products below.


Irritable Bowel Syndrome – Epidemiology – Americas

Clarivate Epidemiology’s coverage of IBS comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of IBS for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe and Japan, and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s IBS forecast will answer the following questions:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of IBS over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts four IBS patient populations, as follows:

  • Total prevalent cases.
  • Constipation-predominant prevalent cases (IBS-C).
  • Diarrhea-predominant prevalent cases (IBS-D).
  • Mixed prevalent cases (IBS-M or IBS-A).

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Ulcerative Colitis – Landscape & Forecast – Disease Landscape & Forecast (G7)
We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s…
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
Report
Crohn’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
The Crohn’s disease (CD) therapy market will grow steadily over the next 10 years as a result of the increasing use of biologics / targeted oral therapies. The well-established TNF-alpha…
Report
Crohn’s Disease – Unmet Need – Unmet Need – Moderate to Severe Crohn’s Disease (US/EU)
Crohn’s disease (CD) is a chronic inflammatory bowel disorder characterized by diarrhea, abdominal pain, and weight loss. Tumor necrosis factor (TNF)-α inhibitors, such as Johnson & Johnson…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms – Claims Data Analysis – IBS-Diarrhea (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. The disorder is grouped into three…